Allegro Ophthalmics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $19.1M

  • Investors
  • 3

Allegro Ophthalmics General Information

Description

Operator of an ophthalmic biopharmaceutical company intended to redefine the retina space with integrin inhibition therapy. The company's lead investigational drug is a broad-spectrum integrin inhibitor, that downregulates oxidative stress upstream, at its source, and simultaneously affects all four pathways of oxidative stress that contribute to retinal diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration, enabling ophthalmologist to treat ocular diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 31473 Rancho Viejo Road
  • Suite 204
  • San Juan Capistrano, CA 92675
  • United States
+1 (949) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allegro Ophthalmics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 09-Sep-2021 $19.1M 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC 09-Jul-2017 000.00 000.00 Completed Clinical Trials - Phase 1
4. Grant 03-Feb-2015 000 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 26-Jan-2015 000.00 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 02-May-2013 $10M $11.5M Completed Clinical Trials - Phase 1
1. Angel (individual) 01-Apr-2012 $1.5M $1.5M Completed Clinical Trials - Phase 1
To view Allegro Ophthalmics’s complete valuation and funding history, request access »

Allegro Ophthalmics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an ophthalmic biopharmaceutical company intended to redefine the retina space with integrin inhibition thera
Drug Discovery
San Juan Capistrano, CA
7 As of 2024
000.00
0000000000 0 000.00

000000

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000 000000000
Stuart, FL
0 As of 0000
0000
000000000000 0000

0000 0

ute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000000000000
Arlington, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allegro Ophthalmics Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stuart Therapeutics Venture Capital-Backed Stuart, FL 0 0000 000000000000 0000
Kala Bio Formerly VC-backed Arlington, MA 00 00000 000000000 00000
Eyevensys Venture Capital-Backed Paris, France 00 000.00 000000 - 000 000.00
Exonate Venture Capital-Backed Cambridge, United Kingdom 00 00.000 00000000000 00.000
Gyroscope Formerly VC-backed London, United Kingdom 00 00000 000000&0 00000
You’re viewing 5 of 24 competitors. Get the full list »

Allegro Ophthalmics Patents

Allegro Ophthalmics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200345805-A1 Compositions and methods useable for treatment of dry eye Inactive 22-Apr-2019 000000000 0
EP-3958915-A4 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019 000000000 0
EP-3958915-A1 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019 000000000
JP-2022529823-A Compositions and methods that can be used to treat dry eye Pending 22-Apr-2019 000000000
CA-3134362-A1 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019 A61K38/08
To view Allegro Ophthalmics’s complete patent history, request access »

Allegro Ophthalmics Executive Team (7)

Name Title Board Seat Contact Info
Hampar Karageozian Ph.D Co-Founder, Co-Chief Executive Officer, Executive Chairman, Chief Technical Officer & President
Vicken Karageozian MD Co-Founder, Co-Chief Executive Officer, President & Board Member
John Park Ph.D Co-Founder, Chief Scientific Officer, Vice President, Manufacturing Development & Board Member
Stephanie Yee Vice President of Finance
You’re viewing 4 of 7 executive team members. Get the full list »

Allegro Ophthalmics Board Members (11)

Name Representing Role Since
Marc Carlson Allegro Ophthalmics Board Member 000 0000
Mark Livingston Allegro Ophthalmics Board Member 000 0000
Rebecca Colbert Self Board Member 000 0000
Ronald Kurtz MD Allegro Ophthalmics Board Member 000 0000
Thomas Bender Allegro Ophthalmics Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Allegro Ophthalmics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allegro Ophthalmics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The Leona M. and Harry B. Helmsley Charitable Trust Limited Partner 000 0000 000000 0
Bausch Health Companies Corporation Minority 000 0000 000000 0
Hanmi Pharm Corporation Minority 000 0000 000000 0
To view Allegro Ophthalmics’s complete investors history, request access »

Allegro Ophthalmics FAQs

  • When was Allegro Ophthalmics founded?

    Allegro Ophthalmics was founded in 2011.

  • Who is the founder of Allegro Ophthalmics?

    Hampar Karageozian Ph.D, Vicken Karageozian MD, and John Park Ph.D are the founders of Allegro Ophthalmics.

  • Who is the CEO of Allegro Ophthalmics?

    Hampar Karageozian Ph.D and Vicken Karageozian MD are the CEOs of Allegro Ophthalmics.

  • Where is Allegro Ophthalmics headquartered?

    Allegro Ophthalmics is headquartered in San Juan Capistrano, CA.

  • What is the size of Allegro Ophthalmics?

    Allegro Ophthalmics has 7 total employees.

  • What industry is Allegro Ophthalmics in?

    Allegro Ophthalmics’s primary industry is Drug Discovery.

  • Is Allegro Ophthalmics a private or public company?

    Allegro Ophthalmics is a Private company.

  • What is Allegro Ophthalmics’s current revenue?

    The current revenue for Allegro Ophthalmics is 000000.

  • How much funding has Allegro Ophthalmics raised over time?

    Allegro Ophthalmics has raised $61.6M.

  • Who are Allegro Ophthalmics’s investors?

    The Leona M. and Harry B. Helmsley Charitable Trust, Bausch Health Companies, and Hanmi Pharm have invested in Allegro Ophthalmics.

  • Who are Allegro Ophthalmics’s competitors?

    Stuart Therapeutics, Kala Bio, Eyevensys, Exonate, and Gyroscope are some of the 24 competitors of Allegro Ophthalmics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »